169 related articles for article (PubMed ID: 19364397)
1. Rapid assessment of the effect of ciprofloxacin on chromosomal DNA from Escherichia coli using an in situ DNA fragmentation assay.
Tamayo M; Santiso R; Gosalvez J; Bou G; Fernández JL
BMC Microbiol; 2009 Apr; 9():69. PubMed ID: 19364397
[TBL] [Abstract][Full Text] [Related]
2. Assessment of Chromosomal DNA Fragmentation by Quinolones in an Isogenic Collection of Escherichia coli with Defined Resistance Mechanisms.
Rodríguez-Martínez JM; Santiso R; Machuca J; Bou G; Pascual Á; Fernández JL
Microb Drug Resist; 2016 Jul; 22(5):354-9. PubMed ID: 26890225
[TBL] [Abstract][Full Text] [Related]
3. Dual targeting of topoisomerase IV and gyrase to reduce mutant selection: direct testing of the paradigm by using WCK-1734, a new fluoroquinolone, and ciprofloxacin.
Strahilevitz J; Hooper DC
Antimicrob Agents Chemother; 2005 May; 49(5):1949-56. PubMed ID: 15855518
[TBL] [Abstract][Full Text] [Related]
4. [Investigation of the effect of efflux pump inhibitors to MIC values of ciprofloxacin in clinical isolates of Pseudomonas aeruginosa, Escherichia coli, Acinetobacter baumannii and Staphylococcus aureus].
Cetinkaya E; Coban AY; Durupinar B
Mikrobiyol Bul; 2008 Oct; 42(4):553-61. PubMed ID: 19149076
[TBL] [Abstract][Full Text] [Related]
5. DNA gyrase and topoisomerase IV on the bacterial chromosome: quinolone-induced DNA cleavage.
Chen CR; Malik M; Snyder M; Drlica K
J Mol Biol; 1996 May; 258(4):627-37. PubMed ID: 8636997
[TBL] [Abstract][Full Text] [Related]
6. [Effect of efflux pump inhibitor 1-(1-naphthylmethyl)-piperazine to MIC values of ciprofloxacin in ciprofloxacin resistant gram-negative bacteria].
Coban AY; Bayram Z; Sezgin FM; Durupinar B
Mikrobiyol Bul; 2009 Jul; 43(3):457-61. PubMed ID: 19795621
[TBL] [Abstract][Full Text] [Related]
7. Ciprofloxacin-resistant Escherichia coli emerging in a rehabilitation medical center.
Canawati HN; el-Farra R; Seymour J; Shimashita J; Dunn D; Montgomerie JZ
Diagn Microbiol Infect Dis; 1997 Nov; 29(3):133-8. PubMed ID: 9401805
[TBL] [Abstract][Full Text] [Related]
8. DNA topoisomerase targets of the fluoroquinolones: a strategy for avoiding bacterial resistance.
Zhao X; Xu C; Domagala J; Drlica K
Proc Natl Acad Sci U S A; 1997 Dec; 94(25):13991-6. PubMed ID: 9391140
[TBL] [Abstract][Full Text] [Related]
9. [Activity of 5 fluoroquinolones on hospital Gram-negative bacilli with different sensitivities to pefloxacin].
Aubert G; Puech C; Lucht F; Loboguerrero M; Denis M; Dorche G
Pathol Biol (Paris); 1989 Oct; 37(8):881-7. PubMed ID: 2515519
[TBL] [Abstract][Full Text] [Related]
10. Prediction of the effects of inoculum size on the antimicrobial action of trovafloxacin and ciprofloxacin against Staphylococcus aureus and Escherichia coli in an in vitro dynamic model.
Firsov AA; Vostrov SN; Kononenko OV; Zinner SH; Portnoy YA
Antimicrob Agents Chemother; 1999 Mar; 43(3):498-502. PubMed ID: 10049257
[TBL] [Abstract][Full Text] [Related]
11. Activities of trovafloxacin compared with those of other fluoroquinolones against purified topoisomerases and gyrA and grlA mutants of Staphylococcus aureus.
Gootz TD; Zaniewski RP; Haskell SL; Kaczmarek FS; Maurice AE
Antimicrob Agents Chemother; 1999 Aug; 43(8):1845-55. PubMed ID: 10428901
[TBL] [Abstract][Full Text] [Related]
12. DNA fragmentation in microorganisms assessed in situ.
Fernández JL; Cartelle M; Muriel L; Santiso R; Tamayo M; Goyanes V; Gosálvez J; Bou G
Appl Environ Microbiol; 2008 Oct; 74(19):5925-33. PubMed ID: 18689511
[TBL] [Abstract][Full Text] [Related]
13. Comparative pharmacodynamics of gatifloxacin and ciprofloxacin in an in vitro dynamic model: prediction of equiefficient doses and the breakpoints of the area under the curve/MIC ratio.
Vostrov SN; Kononenko OV; Lubenko IY; Zinner SH; Firsov AA
Antimicrob Agents Chemother; 2000 Apr; 44(4):879-84. PubMed ID: 10722485
[TBL] [Abstract][Full Text] [Related]
14. Diverse phenotypic and genotypic characterization among clinical Klebsiella pneumoniae and Escherichia coli isolates carrying plasmid-mediated quinolone resistance determinants.
Yang J; Luo Y; Cui S; Wang W; Han L
Microb Drug Resist; 2011 Sep; 17(3):363-7. PubMed ID: 21563956
[TBL] [Abstract][Full Text] [Related]
15. Fluoroquinolone resistance and gyrA and parC mutations of Escherichia coli isolated from chicken.
Lee YJ; Cho JK; Kim KS; Tak RB; Kim AR; Kim JW; Im SK; Kim BH
J Microbiol; 2005 Oct; 43(5):391-7. PubMed ID: 16273029
[TBL] [Abstract][Full Text] [Related]
16. [Mutations of gyrA in ciprofloxacin resistant Escherichia coli strains].
Eraç B; Gill A; Amyes SG; Gülay Z
Mikrobiyol Bul; 2003; 37(2-3):125-30. PubMed ID: 14593893
[TBL] [Abstract][Full Text] [Related]
17. Occurrence of single-point gyrA mutations among ciprofloxacin-susceptible Escherichia coli isolates causing urinary tract infections in Latin America.
Gales AC; Gordon KA; Wilke WW; Pfaller MA; Jones RN
Diagn Microbiol Infect Dis; 2000 Jan; 36(1):61-4. PubMed ID: 10744370
[TBL] [Abstract][Full Text] [Related]
18. Gemifloxacin and ciprofloxacin pharmacodynamics in an in-vitro dynamic model: prediction of the equivalent AUC/MIC breakpoints and doses.
Firsov AA; Zinner SH; Lubenko IYu ; Vostrov SN
Int J Antimicrob Agents; 2000 Dec; 16(4):407-14. PubMed ID: 11118849
[TBL] [Abstract][Full Text] [Related]
19. Comparative pharmacodynamics of the new fluoroquinolone ABT492 and ciprofloxacin with Escherichia coli and Pseudomonas aeruginosa in an in vitro dynamic model.
Zinner SH; Vostrov SN; Alferova IV; Lubenko IY; Portnoy YA; Firsov AA
Int J Antimicrob Agents; 2004 Aug; 24(2):173-7. PubMed ID: 15288317
[TBL] [Abstract][Full Text] [Related]
20. Rapid and simple determination of ciprofloxacin resistance in clinical strains of Escherichia coli.
Santiso R; Tamayo M; Fernández JL; del Carmen Fernández M; Molina F; Villanueva R; Gosálvez J; Bou G
J Clin Microbiol; 2009 Aug; 47(8):2593-5. PubMed ID: 19571026
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
